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Abstract
Background: Elevated serum level of retinol-binding protein 4 (RBP4) has been associated with obesity-related co-
morbidities including insulin resistance, dyslipidemia and hypertension.
Objectives: The present study examined the relationship between serum level of RBP4 and various risk factors related to
cardiovascular disease (CVD) in men and women.
Methods: 284 subjects (139 males, 145 females), grouped into healthy (n = 60), obese diabetes (n = 60), non-obese diabetes
(n = 60), obese non-diabetes (n = 60) and patients with CVD (n = 44), were assessed for anthropometric and biochemical
parameters related to obesity, diabetes and CVD. In addition, serum levels of several adipokines, including fatty acid binding
protein 4 (FABP4) and lipocalin 2 (LCN2) and RBP4 were measured using specific immunoassays.
Results: Serum RBP4 level correlated significantly with principal component derived from known risk factors of CVD
(b= 0.2060.06, P = 0.002). Significance of this correlation was limited to women (b= 0.2060.06, P = 0.002) and it persisted
even after adjusting for BMI (b= 0.1960.06, P = 0.002). Overall (n = 284) serum RBP4 values significantly correlated with
FABP4 (R = 0.19, p = 0.001). Serum FABP4 level of CVD subjects was significantly higher than healthy control (P = 0.001) and
non-obese diabetes (P = 0.04) groups, but this difference was attributable to differences in BMI. Serum LCN2 level correlated
well with RBP4 (R = 0.15, P = 0.008) and FABP4 (R = 0.36, P,0.001), but did not differ significantly between CVD and other
groups.
Conclusions: Results of this study indicate a significant correlation between serum RBP4 and various established risk factors
for CVD and suggest RBP4 may serve as an independent predictor of CVD in women.
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Introduction
Cardiovascular diseases (CVD) are a principal cause of death
worldwide and are linked to obesity and metabolic syndrome.
Several adipokines secreted by the increased adipose tissue mass,
together with the infiltrating macrophages, have been identified as
key components of the ‘adipo-cardiovascular axis’ and are main
contributors to the pathogenesis of atherosclerosis and other
cardiovascular diseases [1,2]. Among these, the lipocalin family
proteins, FABP4, LCN2 and RBP4, have been identified as
adipokines associated with obesity, type 2 diabetes and metabolic
syndrome.
FABP4, a lipid-binding chaperone protein for fatty acids, is one
of the most abundant proteins secreted by mature adipocytes [3]
and also by macrophages [4]. Epidemiological studies in different
ethnic groups demonstrate a close association between serum
levels of FABP4 and a cluster of obesity-related cardiometabolic
risk factors [5–9]. In particular, plasma FABP4 levels are positively
correlated with measures of endothelial dysfunction [10], coronary
atherosclerosis [11] and various types of cardiovascular diseases
[9,12–14].
LCN2 is a 25 kDa glycoprotein that is secreted abundantly by
adipose tissues, and hence elevated in conditions of obesity
[15,16]. Clinical, animal and cellular studies demonstrate its pro-
inflammatory properties and its causal involvement in obesity-
associated metabolic abnormalities [15–18].
RBP4 is the sole carrier of retinol (vitamin A alcohol) in blood
and serves to transport it from liver stores to the peripheral tissues.
In various chronic diseases associated with obesity RBP4 is
produced largely by mature adipocytes [19] and activated
macrophages [20] in the adipose tissue. It is an established
biomarker of adipose tissue mass and obesity in both children and
adults [19–21]. This association of RBP4 with body fat has been
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extended to various obesity-associated metabolic and cardiovas-
cular disorders [19,22–24].
The aim of the present study was to investigate the usefulness of
FABP4, LCN2 and RBP4 as biomarkers of CVD by exploring in
men and women the association between their serum levels and
various known markers related to CVD.
Methodology
Subjects
A total of 284 subjects, 139 males and 145 females, aged
between 51 to 64 years, were selected from the existing Biomarkers
Screening in Riyadh Program (RIYADH Cohort), a capital-wide
study composed of randomly selected individuals from different
Primary Health Care Centers (PHCCs) in Riyadh, Saudi Arabia.
The subjects were categorized into healthy control (n = 60), obese
without diabetes (n = 60), non-obese diabetes (n = 60), obese
diabetes (n = 60) and subjects with history of CVD (n=44). The
CVD subjects had also other conditions including hypertension,
dyslipidemia and diabetes, and the treatment medications
included both cardiovascular and anti-diabetic drugs (insulin,
metformin, statins, aspirin, warfarin, and verapamil). Written and
informed consent was obtained individually from all the partic-
ipants prior to inclusion and commencement of the study. This
study was conducted in accordance with the guidelines of the
Ethics Committee of the College of Science, King Saud
University, by which it was approved.
Clinical and Biochemical Measurements
Clinical and anthropometric parameters, including blood
pressure (BP), weight, height, hip and waist circumferences, and
sagittal abdominal diameter (SAD) were measured following
standard procedures. Body mass index (BMI) was calculated as
weight/height2 (Kg/m2). Fasting blood samples were collected and
glucose, triglycerides, total and HDL-cholesterol, calcium and
phosphorus levels were measured by chemistry auto-analyzer
(Konelab, Espoo, Finland) and concentrations of LDL-cholesterol
were calculated using Friedwald’s formula [25].
Measurement of FABP4 in Human Serum
A sandwich immunoassay specific to human FABP4, developed
by Antibody and Immunoassay Services (AIS), the University of
Figure 1. Serum levels of FABP4, LCN2 and RBP4 in obese subjects with or without diabetes and in CVD patients. The CVD group had
significantly higher level of serum RBP4 compared to any of the other groups. FABP4 values were significantly higher in obese, obese diabetic and
CVD subjects compared to control and non-obese diabetic groups. LCN2 values were higher in CVD subjects than any of the others but this
difference did not reach statistical significance (P = 0.46).
doi:10.1371/journal.pone.0048612.g001
Table 1. Clinical and biochemical parameters of study subjects by group.
Healthy Control
Obese Without
Diabetes
Non-obese
Diabetes Obese Diabetes CVD P Value
N 60 60 60 60 44
M/F 32/28 28/32 27/33 25/35 27/17 0.29
Medications
Anti-diabetic - - 46 55 12 ,0.001
Cardiovascular - 5 7 4 44 ,0.001
Smoking status (%) 18.3 11.6 8.3 10.0 16.0 0.46
Age (year) 51.4613.6 54.3614.2 58.8612.3ab 52.969.5c 64.469.7abcd ,0.001
BMI (kg/m2) 22.961.6 34.763.9a 26.563.1ab 34.062.5ac 29.564.5abcd ,0.001
Waist (cm) 82.5613.4 104.3616.6 92.2618.2 101.1625.3 97.5620.3 ,0.001
Hips (cm) 95.1615.1 115.6616.5a 97.1619.2b 104.4626.3abc 102.1622.5ab ,0.001
SAD (cm) 19.264.4 25.067.4a 23.067.7a 25.466.0a 25.0610.0a ,0.001
Systolic BP (mmHg) 116.5613.4 128.2614.6a 127.0614.6a 123.8612.2a 128.5616.3a ,0.001
Diastolic BP (mmHg) 74.766.6 79.767.0a 79.366.7a 78.567.4a 77.367.7a 0.002
LDL (mmol/L) 3.460.28 3.560.27 3.860.26a 3.460.24 3.060.32abcd 0.006
Triglycerides (mmol/L) 1.560.33 1.760.28 2.360.50ab 2.360.45ab 2.160.41ab ,0.001
HDL (mmol/L) 1.160.38 0.9360.29 0.8860.31a 0.9060.38a 0.7960.29ab 0.04
Glucose (mmol/L) 4.961.2 5.461.2 12.261.3ab 11.861.3ab 8.761.5abcd ,0.001
Cholesterol (mmol/L) 5.261.2 5.461.0 5.961.4ab 5.661.2 5.061.5cd 0.001
Calcium (mmol/L) 2.560.23 2.560.21 2.560.25 2.660.31 2.660.38 0.20
Phosphorus (mmol/L) 1.260.28 1.360.40 1.260.30 1.460.50 1.260.30 0.32
Data represented by mean 6 standard deviation;
aindicates group significantly different from control;
bindicates group significantly different from obese without diabetes;
cindicates group significantly different from non-obese diabetes;
dindicates group significantly different from obese diabetes. Level of significance is given at p#0.05. Abbreviations: BMI, body mass index; SAD, sagittal abdominal
diameter; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
doi:10.1371/journal.pone.0048612.t001
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Hong Kong, was used [13]. A mouse monoclonal antibody specific
for human FABP4 was pre-coated onto a microplate. Human
serum was diluted (1:3) into phosphate-buffered saline (PBS)
(10 mmol/L sodium phosphate, 137 mmol/L NaCl, 2.7 mmol/L
KCl, pH 7.4), and 100 mL of the diluted samples or recombinant
standards were applied to each well and incubated at 37uC for one
hour. The plates were washed three times and then incubated with
100 mL of biotin-labeled polyclonal antibody specific to human
FABP4 for another hour. After being washed three more times
with PBS, the wells were incubated with streptavidin-conjugated
horseradish peroxidase for one hour and subsequently reacted
with tetramethyl-benzidine reagent for 15 minutes. A total of
100 mL of 2 mol/L H2SO4 was added to each well to stop the
reaction, and the absorbance at 450 nm was measured using a
micro-plate reader. The inter- and intra- assay variations were
4.5–5.7% and 4.1–6.5%, respectively.
Measurement of LCN2 in Human Serum
Serum levels of LCN2 were quantified using a monoclonal
antibody-based immunoassay developed by AIS as described
before [26]. Human serum was diluted (1:50) into PBS, and
100 mL of the diluted samples or recombinant LCN2 standards
were applied to each well of a microplate precoated with a
monoclonal antibody specific to LCN2, followed by incubation at
37uC for one hour. The plates were then washed three times and
incubated with 100 mL of horseradish peroxidase (HRP)-linked
monoclonal antibody specific to human LCN2 for another hour.
After another extensive washing step, the wells were incubated
with tetramethyl-benzidine reagent for 15 minutes. A total of
100 mL of 2 mol/L H2SO4 was added to each well to stop the
reaction, and the absorbance at 450 nm was measured using a
micro-plate reader. Since the increases in absorbance were directly
proportional to the amount of captured human LCN2, the sample
concentration was calculated from a reference curve. The inter-
and intra- assay variations were 5.7–7.6% and 4.8–6.5%,
respectively.
Measurement of RBP4 in Human Serum
Serum RBP4 was measured by a monoclonal antibody-based
rapid immunoassay developed by AIS [13]. Human serum was
diluted (1:2000) into phosphate-buffered saline (PBS), and 100 mL
of the diluted samples or recombinant RBP4 standards were
applied to each well of a microplate precoated with a monoclonal
antibody specific to human RBP4, followed by incubation at 37uC
for one hour. The plates were then washed three times and
incubated with 100 mL of HRP-linked monoclonal antibody
specific to human RBP4 for another hour. After extensive
washing, the wells were incubated with tetramethyl-benzidine
reagent for 15 minutes, followed by the addition of 100 mL of
2 mol/L H2SO4 to stop the reaction. The absorbance at 450 nm
was measured using a micro-plate reader, and RBP4 concentra-
tion in the samples calculated from a reference curve. The inter-
and intra- assay variations were 5.2–8.1% and 6.3–7.8%,
respectively.
Statistical Analysis
Variables are presented as mean 6 standard deviation. All
variables were checked for normality. Non-Gaussian variables
were either square root or log transformed. Group comparisons
Table 2. Establishment of principal components.
Rotated Component Loadings
CDV risk factors Component 1 Component 2
Age 0.79 20.11
Cholesterol (mmol/L) 0.31 0.48
HDL (mmol/L) 20.21 0.90
Systolic BP (mmHg) 0.81 0.14
Eigen value 1.42 1.1
Percentage of variance explained by each component (%) 35.5 26.5
Cumulative percentage 35.5 62.0
Eigen vectors (factor loadings for standardized variables) for first two principal components.
doi:10.1371/journal.pone.0048612.t002
Table 3. Pearson correlations of CVD component 1 and BMI
with anthropometric and biochemical parameters in CVD
subjects.
CVD
Component 1 BMI Glucose
R P value R P value R P value
Age 0.79 ,0.001 0.01 0.78 0.11 0.06
BMI (kg/m2) 0.05 0.36 1 - 0.07 0.22
Waist (cm) 0.07 0.24 0.48 ,0.001 0.05 0.38
Hips (cm) 20.04 0.55 0.46 ,0.001 20.05 0.42
SAD (cm) 0.17 0.01 0.37 ,0.001 0.17 0.007
Systolic BP (mmHg) 0.81 ,0.001 0.17 0.005 0.10 0.10
Diastolic BP (mmHg) 0.53 ,0.001 0.22 0.001 0.10 0.09
LDL (mmol/L) 0.30 ,0.001 20.06 0.32 0.08 0.14
Triglycerides
(mmol/L)
0.25 ,0.001 0.006 0.92 0.33 ,0.001
HDL (mmol/L) 20.20 0.002 0.02 0.70 20.05 0.41
Glucose (mmol/L) 0.15 0.02 0.07 0.22 1 -
Cholesterol
(mmol/L)
0.32 ,0.001 20.03 0.65 0.24 ,0.001
Calcium (mmol/L) 0.09 0.21 20.02 0.76 0.20 0.003
Phosphorus (mmol/L) 0.01 0.82 0.16 0.01 0.02 0.79
FABP4 (ng/mL) 0.05 0.43 0.13 0.02 0.02 0.74
LCN2 (ng/mL) 20.03 0.62 20.01 0.84 20.05 0.41
RBP4 (ng/mL) 0.20 0.002 20.07 0.18 20.06 0.33
doi:10.1371/journal.pone.0048612.t003
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were carried out using Analysis of variance (ANOVA) followed by
the LSD post hoc test. Chi-Square analysis was used to compare
categorical variables. Principal component analysis was used to
account for the primary risk factors for CVD. Principal
component analysis transforms the original variables into a new
set of uncorrelated factors (principal components) that account for
the maximal proportion of the variance in the data, with each
component being a linear combination of the original observed
variables [27–29]. Principal component 1 was the linear combi-
nation of variables that accounted for the largest proportion of
variance in the data. Numbers of components were retained based
on the following rules: (a) Eigen values of 1 or greater or (b)
components above the break in the scree plot. A varimax rotation
was used to obtain set interpretable components. The components
were interpreted based on the loadings of risk factors. Principal
component scores were calculated for each subject. Pearson’s
correlation was used to assess variation between variables of
interest and component scores. Linear regression models were
used to examine the association of principal component scores
with RBP4 levels. Three linear models were generated, adjusting
for age and BMI for each gender. Statistical analysis was
performed using SPSS version 16.0 (Statistical package for Social
Science, Inc., Chicago IL, USA), and a level of significance was
accepted when p was less than 0.05.
Results
Since FABP4, LCN2 and RBP4 have been reported to relate to
insulin resistance and metabolic syndrome, the serum values of
these adipokines were measured in a Saudi population grouped
into healthy control, obese without diabetes, non-obese diabetes,
obese diabetes and subjects with CVD, to explore their potential as
biomarkers for CVD (Figure 1). FABP4 values were significantly
higher in obese (2.260.86 ng/mL), obese diabetes (2.360.87 ng/
mL) and CVD subjects (2.760.90 ng/mL) compared to control
(1.0160.51 ng/mL) and non-obese diabetes (1.660.77 ng/mL)
groups. However, BMI adjusted FABP4 values of the healthy
control and CVD groups were not significantly different (P = 0.18).
Serum LCN2 values did not show any significant difference
between these groups. RBP4 values were significantly higher in
CVD compared to any of the other groups (P = 0.04).
Mean values of various clinical and biochemical parameters
measured in different groups are given in Table 1. CVD group
showed significant differences with respect to the following
parameters: CVD group had lower BMI values than both the
obese groups; LDL of CVD was lower than all the other groups;
triglyceride value of CVD was lower than that of healthy control
and obese non-diabetes groups.
CVD risk score is a risk assessment tool, developed by National
Cholesterol Education Program (NCEP) for estimating 10 year risk
of having a heart attack, by including various risk factors like age,
gender, total cholesterol, HDL smoking status and systolic blood
pressure in the analysis. Principal component analysis (PCA) is a
mathematical technique that transforms a number of correlated
variables into a reduced number of uncorrelated variables called
principal components, of which the first principal component
captures the maximal variance [27–29]. Hence, the first principal
component derived from different risk factors would be an efficient
way to quantify the risk of developing CVD.
We performed the principal component analysis, by including
all the continuous parameters mentioned above, on subjects of all
groups, including CVD. Two principal components were selected
based on Eigen values (.1) and scree plots (Table 2). All
categorical parameters were analyzed by stratification. Compo-
nent 1 carries all major risks of developing CVD according to
NCEP criteria. Components 1 and 2 explained 35.5% and 26.5%
of total variance, giving a cumulative percentage of 62.0%. The
highest loaded components were systolic blood pressure (0.81) and
age (0.79).
Table 4. RBP4 in CVD subjects correlated to component 1.
RBP4 as
dependent
variable Parameters Overall Female Male
b ± standard error P value b± standard error P value b± standard error P value
Model-1 Component 1 0.2060.06 0.002 0.2060.06 0.002 0.0660.12 0.63
Model-2 Component 1 0.2260.06 0.001 0.1960.06 0.002 0.0960.12 0.47
BMI 20.0860.06 0.22 0.0360.06 0.62 20.1560.12 0.21
Linear regression models were used to examine the association of principal component scores with RBP4 levels. Model-1 unadjusted; model-2 adjusted for BMI.
doi:10.1371/journal.pone.0048612.t004
Table 5. Correlation analysis of anthropometric and clinical
parameters with serum RBP4, FABP4 and LCN2.
Overall (N=284) RBP4 (ng/mL)
FABP4
(ng/mL) LCN2 (ng/mL)
R p value R p value R p value
N 284 284 284
Age (year) 0.15 0.008 0.18 0.002 20.06 0.27
BMI (kg/m2) 20.10 0.09 0.25 ,0.001 20.01 0.84
Waist (cm) 0.002 0.97 0.21 ,0.001 0.08 0.16
Hips(cm) 20.08 0.16 0.20 0.001 0.03 0.65
SAD (cm) 20.01 0.81 0.24 ,0.001 0.04 0.47
Systolic BP (mmHg) 0.10 0.10 0.15 0.01 20.06 0.32
Diastolic BP (mmHg) 0.05 0.35 0.18 0.004 0.03 0.62
LDL (mmol/L) 0.02 0.69 20.12 0.05 0.13 0.03
Triglycerides (mmol/L) 0.28 ,0.001 0.05 0.55 0.23 0.03
HDL (mmol/L) 20.06 0.33 0.04 0.48 20.13 0.02
Glucose (mmol/L) 20.03 0.59 0.06 0.27 20.05 0.40
Cholesterol (mmol/L) 0.10 0.07 20.07 0.25 20.02 0.72
Calcium (mmol/L) 0.14 0.04 0.02 0.78 20.02 0.75
Phosphorus (mmol/L) 0.02 0.75 0.06 0.34 0.14 0.03
FABP4 (ng/mL) 0.19 0.001 - - 0.36 ,0.001
RBP4 (ng/mL) - - - - 0.15 0.008
doi:10.1371/journal.pone.0048612.t005
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To assess the validity of PCA, Pearson correlation analysis of
CVD component 1 with anthropometric and biochemical
parameters in CVD subjects was performed (Table 3). In addition
to the parameters comprising component 1, established risk
factors, including LDL (R= 0.30, p,0.001) and triglyceride
(R= 0.25, P,0.001) of CVD group, showed significant association
with component 1. However, clinical parameters relevant to CVD,
namely, LDL, triglyceride, HDL and total cholesterol did not
show any significant association with BMI. Serum levels of FABP4
and LCN2 in CVD subjects did not correlate significantly with
component 1. Serum RBP4 values in CVD subjects correlated
significantly with component 1 (b=0.2060.06, P = 0.002), but not
with BMI or glucose levels.
Component 1 values of the CVD subjects were analyzed
according to gender (Table 4). The gender adjusted component 1
values showed significant correlation with RBP4 only in women
(b=0.2060.06, P= 0.002). In female CVD subjects, component 1
values were significantly correlated to RBP4 even after adjusting
the data for BMI (b=0.1960.06, P = 0.002).
To validate RBP4 as a predictive marker of CVD, correlation
analysis of anthropometric and clinical parameters with serum
RBP4, FABP4 and LCN2 values of the overall study subjects
(n = 284) was performed (Table 5). Correlation analysis of the
three measured adipokines revealed that serum FABP4 level
correlated significantly with parameters associated with obesity,
including BMI (R= 0.25, P= 0.002) and systolic (R= 0.15,
P = 0.01) and diastolic (R= 0.18, P= 0.004) blood pressure. On
the other hand, LCN2 concentration correlated significantly with
LDL (R= 0.13, P = 0.03) and triglyceride (R= 0.23, P= 0.03), and
were inversely related to HDL (R=20.13, P= 0.02). Serum
RBP4 values were significantly associated with age (R= 0.15,
P = 0.008), triglycerides (R= 0.28, p,0.001), calcium (R= 0.14,
P = 0.04), FABP4 (R= 0.19, P = 0.001) and LCN2 (R= 0.15,
P = 0.008).
Analysis of the influence of gender on the level of each of these
three biomarkers in CVD subjects indicated significant differences
only for RBP4 and this difference was seen across all the groups
except obese diabetic patients (Table S1).
Discussion
Data from 284 Saudi subjects, grouped into healthy, obese
diabetes, non-obese diabetes, obese non-diabetes and patients with
CVD, provide evidence supporting a biomarker role for serum
RBP4 for CVD. Serum RBP4 levels of CVD subjects correlated
well with ‘component 19, a measure of CVD risk occurring over
the next 10 years, calculated based on different risk factors
established by NCEP. In our data, component 1 correlated well
with many components of the CVD. Even though RBP4, FABP4
and LCN2 levels correlated significantly with each other in the
entire study population (n= 284) and FABP4 levels were
significantly higher in CVD subjects than in healthy control,
FABP4 levels did not differ significantly from that of obese subjects
and LCN2 levels did not differ significantly in CVD compared to
healthy control or other groups. Neither component 1 nor RBP4
showed significant association with BMI of CVD subjects,
indicating RBP4 as marker independent of obesity. Further
analysis showed that the association between RBP4 and compo-
nent 1 was limited only to women, and here the correlation
remained significant even after adjusting the data for BMI. Thus,
results from this study lend support to earlier suggestions that
RBP4 may serve as an independent marker of CVD in women.
Several studies substantiate a link between RBP4 and CVD.
Multiple regression analysis in a Japanese study revealed that
serum RBP4 level was significantly related to systolic BP
independently of age, sex, BMI, and total cholesterol level [19];
in another Japanese study, plasma RBP4 levels in the subjects with
cerebral infarction were significantly greater than those in control
subjects [20]. The present data show significantly higher systolic
blood pressure in CVD compared to healthy control group as well
as a close association between component 1 and systolic blood
pressure in the CVD group. RBP4 levels were increased in
hypertensive women and correlated with the degree of carotid
intima-media thickness (IMT), suggesting a role for this adipokine
in the modulation of the atherosclerotic process exerted by the
adipose tissue [17]. A recent study found elevated serum RBP4 to
be associated with small dense low-density lipoprotein cholesterol
(sdLDL-C) and oxidized low-density lipoprotein (ox-LDL) levels in
dyslipidemic subjects [30].
A previous study reported subcutaneous adipose tissue-derived
RBP4-mRNA expression to be gender specific and higher in
women [31]. Studies have also shown gender differences in the
nature and frequency of CVD. Acute coronary syndrome with
normal coronary arteries (non-obstructive CAD) were found to be
more common in women (10–25%) when compared to men (6–
10%) [32,33] suggesting that, in women, atherosclerosis can occur
with seemingly normal coronary arteries. Plaque erosion,
compared with the classic plaque fissure and rupture, as the
etiology of coronary thrombosis, was more frequent in women
than in men (37 compared with 18%, respectively) [32,33]. The
gender bias in atherogenesis was attributed to effects of the sex
steroids (oestrogens, androgens and progestins) on various cell
types involved in the disease process [34]. In this context,
correlation between RBP4 and CVD in women may be indicative
of a causative link.
In our study, in addition to RBP4 various cardiometabolic risk
factors like age, BMI, systolic blood pressure, triglyeride and HDL
levels were significantly associated with CVD compared to healthy
control group. However, a study involving 709 recent postmen-
opausal women showed only a weak correlation between elevated
serum RBP4 and higher triglycerides levels, but no additional
associations between RBP4 levels and other cardiometabolic risk
factors [35]. In another study involving 473 subjects, RBP4
positively correlated with triglycerides but not with other
cardiometabolic risk factors [28]. Our study did not show any
association between serum LCN2 levels and CVD, even though
LCN2 levels correlated significantly with FABP4 and RBP4 in the
entire study population. Plasma LCN2 was found to be a
significant predictor of CVD associated mortality, independent
of traditional risk factors, in older adults [36].
Previous studies have associated serum RBP4 levels to obesity,
insulin resistance and components of the metabolic syndrome
[19,21]. RBP4 level was positively associated with visceral fat and
LDL-cholesterol levels, independently of body weight, in a study
involving 102 women and the study authors suggested a causative
link between visceral fat derived RBP4 and CVD in women [37].
Furthermore, RBP4 level was increased in serum of lean and obese
insulin-resistant humans compared to insulin-sensitive humans,
indicating that higher RBP4 may reflect insulin-resistance
independently of obesity [8]. In another study, circulating RBP4
levels were independent of adipose tissue secreted RBP4, which is
supported by the finding that RBP4 mRNA transcription in obese
persons, as compared to lean subjects, increased 60-fold in visceral
fat and only 12 fold in subcutaneous fat [38].
In our study, FABP4 levels in CVD subjects were significantly
higher than in healthy controls. However, FABP4 levels in both
obese diabetes and obese non-diabetes subjects also differed
significantly from non-obese subjects confirming the previously
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reported specificity of FABP4 as a biomarker of adipose tissue
mass. Hence, it is clear from the results that FABP4 level is not a
marker differentiating CVD from obesity in the studied popula-
tion.
There were some limitations to our study. Our study subjects
consisted men and women of Saudi ethnicity, and hence the
generalizability to other ethnicities is unknown. Even though
several potential risk factors of CVD were included in our analysis,
the role of some unknown or unmeasured confounders cannot be
ruled out.
In summary, results of our study imply that the measurement of
serum levels of RBP4 in women can be considered along with
other cardiovascular risk factors in a larger clinical setting, as a
valuable predictor of the risk of developing major cardiovascular
events. Also, determining RBP4 levels in serum may help to
improve understanding of the disease process, to obtain prognostic
information, and to guide and follow the efficacy of cardiovascular
therapies.
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